Key facts
- This page summarizes Mark E. Sims's Form 3 filing for Candel Therapeutics, Inc. (CADL).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jul 2026, 16:11.
Mark E. Sims - 06 Jul 2026 Form 3 Insider Report for Candel Therapeutics, Inc. (CADL)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- CADL
- Reported as of
- 06 Jul 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Charles Schoch, as Attorney-In-Fact for Mark E. Sims
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Mark E. Sims filed Form 3 for Candel Therapeutics, Inc. (CADL) on 08 Jul 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002139479
Primary reporting owner
Sims Mark E.
- Relationship
- Chief Commercial Officer
- Address
- C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK STREET, SUITE 450, NEEDHAM
- Signature
- /s/ Charles Schoch, as Attorney-In-Fact for Mark E. Sims
- Signature date
- 08 Jul 2026
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
Exhibit 24 - Power of Attorney